$JNJ Headlines J&J to buy Alios BioPharma for $1.75

New Post Public Reply Private Reply Replies (0) Message Board

Oct 6, 2014 at 11:44 AM

$JNJ Headlines

J&J to buy Alios BioPharma for $1.75 billion 9:23 a.m. Sept. 30, 2014 - Tess Stynes
Inovio, GeneOne to move Ebola vaccine to human trials 11:42 a.m. Sept. 24, 2014 - Erin McCarthy
Dow industrials take flight, rally to uncharted territory 10:31 a.m. Sept. 19, 2014 - Michael Ashbaugh
7 reasons to be bullish on Microsoft 6:00 a.m. Sept. 18, 2014 - Jeff Reeves
5 pretty amazing facts about Alibaba 9:54 a.m. Sept. 15, 2014 - Tim Mullaney
Here’s what history says about the stock market in September 5:39 a.m. Sept. 2, 2014 - Mark Hulbert
This one stock sector can withstand all the ‘bubble’ talk 6:00 a.m. Aug. 21, 2014 - Jeff Reeves
Timing this market is guaranteed to make you a loser 1:02 p.m. Aug. 8, 2014 - Mark Hulbert
You don’t have to be a mega-mind to get this trade right 7:54 a.m. Aug. 6, 2014 - Jim Lowell
Mega caps with mega recommendations 7:54 a.m. Aug. 6, 2014 - Mark Hulbert
These eight health-care stocks could rise up to 75% 1:48 p.m. Aug. 5, 2014 - Philip van Doorn
J&J to call for voluntary return of morcellators 5:30 p.m. July 30, 2014 - MarketWatch.com
Chipotle tops S&P 500, Herbalife ignores ‘death blow’ 1:14 p.m. July 22, 2014 - MarketWatch
Johnson & Johnson sets $5 billion share buyback 5:20 p.m. July 21, 2014 - Jim Jelter
Two rules of thumb for dumping your financial adviser 2:36 p.m. July 18, 2014 - Mark Hulbert
Dow ekes out a gain, but S&P falls; Yellen knocks biotechs and social media: live blog recap 3:04 p.m. July 15, 2014 - blogs.marketwatch.com
Johnson & Johnson shares dip on cautious outlook 10:55 a.m. July 15, 2014 - blogs.marketwatch.com
Plug Power rallies; Lorillard drops on Reynolds merger 10:40 a.m. July 15, 2014 - Angela Johnson
Newscast: NBA wants to double TV fees 9:59 a.m. July 15, 2014 - MarketWatch
Johnson & Johnson tops forecasts, boosts outlook 7:57 a.m. July 15, 2014 - MarketWatch.com

Should A Dividend Growth Investor Even Consider A Company Like Seadrill? 9:47 a.m. Today - Seeking Alpha
Corrections & Amplifications 9:32 p.m. Oct. 3, 2014 - The Wall Street Journal Interactive Edition
Health Care, Tech Names Offer Dividend Growth, Stability 5:29 p.m. Oct. 3, 2014 - Investors Business Daily
The Question Isn't If Gilead's Hep C Combo Will Be Approved In The US By Next Friday; The Question Is The Price Of The Regimen 12:12 p.m. Oct. 3, 2014 - Seeking Alpha
Roche Presents Data on Cancer Immunotherapy Candidate - Analyst Blog 9:50 a.m. Oct. 3, 2014 - Zacks.com
Biotech Stock Mailbag: Seattle Genetics, Achillion, Catalyst Pharma 9:41 a.m. Oct. 3, 2014 - TheStreet.com
Will Gilead Sciences Score Healthy Gains For Investors? 12:03 p.m. Oct. 2, 2014 - Investors Business Daily
High-Yield Portfolio Still Yielding 8% After 18 Months 11:00 a.m. Oct. 2, 2014 - Seeking Alpha
GeoVax jumps on the Ebola bandwagon 10:35 a.m. Oct. 2, 2014 - Seeking Alpha
Makers of the 10 Top-Selling Cancer Drugs Catch the Eye of Analyst 8:02 a.m. Oct. 2, 2014 - 247WallSt.com
Sure Bets: Slow-Changing Industries for Long-Term Investors 5:48 p.m. Oct. 1, 2014 - GuruFocus.com
AbbVie Announces Positive Results on Oncology Candidate - Analyst Blog 4:30 p.m. Oct. 1, 2014 - Zacks.com
Johnson & Johnson Falls On Bernstein Downgrade 2:09 p.m. Oct. 1, 2014 - benzinga.com
Why Gilead Sciences (GILD) Stock Is Declining Today 1:07 p.m. Oct. 1, 2014 - TheStreet.com
Bayer closes acquisition of consumer care business of Merck & Co., Inc. for USD 14.2 billion 12:58 p.m. Oct. 1, 2014 - CNW Group
FDA publishes guidance on med device cybersecurity 10:05 a.m. Oct. 1, 2014 - Seeking Alpha
Abbott Labs Completes CFR Pharmaceuticals Acquisition - Analyst Blog 9:50 a.m. Oct. 1, 2014 - Zacks.com
Why Johnson & Johnson (JNJ) Stock Is Lower Today 9:36 a.m. Oct. 1, 2014 - TheStreet.com
Bernstein Downgrades Johnson & Johnson To Market Perform, Shares Drop 7:13 a.m. Oct. 1, 2014 - benzinga.com
Buy ‘Aristocrat’ Funds for the Quality, Not the Dividend Yield 4:32 a.m. Oct. 1, 2014 - InvestorPlace.com

Physicians Value Long-acting and FDC Antidiabetic Agents, Although Competitive Pricing Will Be Needed for Favorable Reimbursement 11:00 a.m. Oct. 1, 2014 - PR Newswire - PRF
Legal Settlement, Data Presentation, Welfare Initiatives, Acquisition Talks, and Study Results - Research Reports on Shire, Merck, Medtronic, Salix and Johnson & Johnson 9:10 a.m. Oct. 1, 2014 - PR Newswire - PRF
Defective Surgical Product Lawsuits Filed Against Johnson & Johnson 2:21 p.m. Sept. 30, 2014 - BusinessWire - BZX
Alios BioPharma Announces Acquisition Agreement With Johnson & Johnson 8:30 a.m. Sept. 30, 2014 - Marketwire
Johnson & Johnson Announces Agreement To Acquire Alios BioPharma 8:30 a.m. Sept. 30, 2014 - PR Newswire - PRF
The Spooky Truth: What You Need To Know About Contact Lens Hygiene 7:17 a.m. Sept. 30, 2014 - PR Newswire - PRF
Pharma Stocks Review - AbbVie, Merck, Johnson and Johnson, GlaxoSmithKline, and Bristol-Myers Squibb 9:20 a.m. Sept. 25, 2014 - PR Newswire - PRF
Latin America Home Healthcare Market (By Device Types: Diagnostics and Monitoring Devices, Therapeutic Home Healthcare Devices, Mobility Assist Devices and Medical Supplies; By Services...) - Industry Analysis, Size, Share, Growth, Trends and Forecast, 20 5:02 p.m. Sept. 24, 2014 - PR Newswire - PRF
In Vitro Diagnostics (POC/Rapid diagnostics) Global market - Forecast to 2020 3:46 p.m. Sept. 24, 2014 - PR Newswire - PRF
The Prostate Cancer Therapeutics Market Forecast 2014-2024 : Opportunities for Leading Companies 5:40 p.m. Sept. 23, 2014 - PR Newswire - PRF
Wearable Technology Market Report 2014-2019 4:15 p.m. Sept. 23, 2014 - PR Newswire - PRF
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results 2:00 p.m. Sept. 23, 2014 - PR Newswire - PRF
Regulatory Approval, Presentation of Data, Appointment, Clinical Study Results, and Increase in Quarterly Dividend - Research Reports on Johnson & Johnson, Merck, Medtronic, Amgen and Covidien 9:05 a.m. Sept. 23, 2014 - PR Newswire - PRF
OxySure Systems Selected for USPTO / Smithsonian Innovation Expo 8:02 a.m. Sept. 23, 2014 - ACCESSWIRE
Twenty Employers to Attend Annual Life Science Hiring Event Next Week 9:00 a.m. Sept. 22, 2014 - PR Newswire - PRF
Mr. David Guerette Joins Matamec's Board of Directors 3:01 p.m. Sept. 19, 2014 - Marketwire
New Product Launch, Accelerated Drug Approvals, Study Initiation, and Market Activity - Research Reports on Johnson & Johnson, Merck, Medtronic, Pharmacyclics and NPS Pharma 9:15 a.m. Sept. 15, 2014 - PR Newswire - PRF
Sirius Solutions names Jessica Harris Director of Supply Chain Practice - Dallas/Ft. Worth Office 10:52 a.m. Sept. 12, 2014 - PR Newswire - PRF
Facial Care Market - Asia-Pacific Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2013 - 2019 8:48 p.m. Sept. 10, 2014 - PR Newswire - PRF
Transvaginal Mesh Lawsuit Latest Update News: J&J's Ethicon Loses another Mesh Trial 5:00 a.m. Sept. 9, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Miracle League Marks Two Decades with Big Fundraising Win

A Double Decade Celebration of Dream and Dedication The Miracle League of the Triangle sure knows how to throw a party—for them, it's not just a gala; it's a testament to two decades of turning dreams into reality. On October 13th, over 300 guests gathered at the Angus Barn Pavilion in Cary, NC, proving that passion for inclusive baseball is just as alive as it was 20...

Extra Mile Day: 18 Years of Honoring Unsung Heroes

Pedaling for Purpose: A Journey That Sparked a Movement What started as a lone journey across America's roads has turned into a celebrated movement to honor those who often go unnoticed. Back in 2009, Shawn Anderson embarked on an unusual journey. Armed only with a bicycle and determination, he pedaled from San Francisco to Boston—over 4,000 miles in just 90 days. It...

Fidelis Care Opens $120K Workforce Grants for Aid

Fidelis Care Steps Up Workforce Engagement Fidelis Care's latest move introduces a fresh shot at tackling two birds with one stone—economic and health stability for Medicaid members. The Workforce Pathways to Health and Economic Mobility grants present up to $120,000 in support for New Yorkers, an attempt aimed squarely at reducing the vicious cycle that traps many in...

Nelson Peltz Doubles Down: Burgers or Pucks?

Mixing Hockey and Hamburgers: The Peltz Way You'd think a guy like Nelson Peltz wouldn't be juggling hockey sticks and hamburgers at the same time, but here we are. The man, a mogul of sorts with Trian Fund Management, is hopping onto a board seat with a New York hockey company and, oh, by the way, throwing a non-binding $7.35-a-share cash proposal to snatch up Wendy's, a...

Jamaica's Tourism Rebounds Post-Hurricane Challenges

Weathering the Storm: A New Chapter for Jamaica It's been nearly a year since Hurricane Melissa hit, and Jamaica is proving that it won't be pushed around by nature's whims. The island's tourism industry, once battered, is now showing remarkable resilience. With hotels and villas reopening and shaking off the dust, it's safe to say Jamaica is back on its feet, and it's...

Virginia Cancer Specialists: Leaders in Trusted Cancer Care

Decades of Trust in Cancer Care Virginia Cancer Specialists isn't just another name in the sea of healthcare providers. That pride they're feeling? Well, they've got every right to it. Just slapped their physicians' names all over the latest Washingtonian's Top Doctors list for 2026. And this isn’t some under-the-table handshake deal. No, this list is shaped by peer...

Genefluence Launches Rapid UTI PCR Test at Chelsea Hospital

There's a fresh breeze blowing through the dusty corridors of healthcare, shaking things up for the better. You see, Genefluence, the brainchild of Professor Chris Toumazou, isn't just throwing a bunch of tech jargon around—it's setting the stage for a much-needed shake-up in how we handle urinary tract infections (UTIs) and, believe me, it couldn’t have come sooner....

Unicycive Faces Legal Heat: Shareholder Lawsuit Looms

The Unicycive Landslide: What Went Down? Investors, buckle up. Unicycive Therapeutics Inc. (NASDAQ: UNCY) finds itself deep in the muck of a securities class action. Chief honchos, CEO Shalabh Gupta and CFO John Townsend, are taking the heat for allegedly controlling company disclosures that led shareholders to believe in non-existent progress with their third-party...

Infoya Surges with 665% Growth, Wins Fast 50 Spot

From Humble Beginnings to High Achiever Alright, let's touch base on Canada's tech landscape for a moment. Infoya's leap into Deloitte's 2026 Technology Fast 50 isn't just a pat on the back—it's a flashing neon sign of what raw ambition mixed with a pinch of AI can cook up for you. They've banked a whopping 665% revenue growth from 2022 to 2025. Not bad for a company...

Heritage Wines Meet Non-Alcoholic Trend: New Deal

Wine Industry Shifts Gears Well, here's a twist that might just shake up the wine racks. C. Mondavi & Family, from the historic Charles Krug estate, is aligning with Missing Thorn—a name gaining traction in the non-alcoholic wine scene. It’s a move that not only raises eyebrows but could also expand your wine-tasting options come your next sober night out. So what...